Payment overview · 2025
General Payments
$249.32
11 reported records · 6 companies
Healthcare provider profile · identity verified
Amy Jo Harmasch, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MOON TWP, PA · NPI 1588808802
Verified facts
What the public records show
CMS Open Payments records show Amy Jo Harmasch, M.D. received $249.32 in general payments during 2025 across 11 reported records.
Novo Nordisk Inc accounted for 30.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $75.96 | 30.5% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $53.61 | 21.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $43.65 | 17.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.82 | 13.6% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.77 | 8.7% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $20.51 | 8.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $249.32 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $53.61 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $50.64 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.82 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.82 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $25.32 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $25.32 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $24.74 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.51 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $21.77 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $20.51 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $20.51 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 66 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
63 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
66 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 505 | 146 |
| Levothyroxine Sodium | Levothyroxine Sodium | 289 | 74 |
| Lisinopril | Lisinopril | 273 | 80 |
| Amlodipine Besylate | Amlodipine Besylate | 262 | 65 |
| Omeprazole | Omeprazole | 226 | 62 |
| Losartan Potassium | Losartan Potassium | 194 | 56 |
| Simvastatin | Simvastatin | 163 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 138 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 136 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 129 | 35 |
| Gabapentin | Gabapentin | 121 | 33 |
| Alendronate Sodium | Alendronate Sodium | 119 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 116 | 37 |
| Sertraline Hcl | Sertraline Hcl | 114 | 34 |
| Metformin Hcl | Metformin Hcl | 108 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 88 | 18 |
| Famotidine | Famotidine | 80 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 80 | 12 |
| Eliquis | Apixaban | 77 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 69 | 19 |
| Furosemide | Furosemide | 67 | 19 |
| Lorazepam | Lorazepam | 67 | 14 |
| Atenolol | Atenolol | 66 | 19 |
| Ozempic | Semaglutide | 66 | 11 |
| Potassium Chloride | Potassium Chloride | 66 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 19 |
| Synthroid | Levothyroxine Sodium | 63 | 15 |
| Metformin Hcl Er | Metformin Hcl | 60 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 60 | 13 |
| Ibandronate Sodium | Ibandronate Sodium | 53 | 18 |
| Trazodone Hcl | Trazodone Hcl | 53 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 52 | 14 |
| Tramadol Hcl | Tramadol Hcl | 52 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 26 |
| Buspirone Hcl | Buspirone Hcl | 50 | 14 |
| Donepezil Hcl | Donepezil Hcl | 50 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 13 |
| Glimepiride | Glimepiride | 46 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 45 | 13 |
| Carvedilol | Carvedilol | 38 | 11 |
| Ezetimibe | Ezetimibe | 38 | 13 |
| Azelastine Hcl | Azelastine Hcl | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Valsartan | Valsartan | 35 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Irbesartan | Irbesartan | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 30 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Meloxicam | Meloxicam | 29 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Alprazolam | Alprazolam | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Clonazepam | Clonazepam | 28 | suppressed |
| Risperidone | Risperidone | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | 12 |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 20 |
| Amoxicillin | Amoxicillin | 23 | 21 |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 22 | suppressed |
| Lactulose | Lactulose | 22 | suppressed |
| Allopurinol | Allopurinol | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | 12 |
| Prednisone | Prednisone | 19 | 13 |
| Tradjenta | Linagliptin | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | 11 |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | 11 |
| Spironolactone | Spironolactone | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Pregabalin | Pregabalin | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 11 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $249.32 · 11 records | Novo Nordisk Inc | AREXVY, Fluad, Flucelvax, GVOKE HYPOPEN, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error